Mode of Action– BOTOXCosmetic.com

Materials for Network Members

Administering BOTOX^® Cosmetic

Clinical Information

	Physician Assessment
	Patient Assessment
	No Downtime
	Mode of Action
	Slide Kits

Professional Organizations

Information for Consumers

The only approved treatment to target the source of glabellar lines¹
To view the mode-of-action video, choose your connection speed to play the movie:

Dial-up

Broadband

Mode-of-action Highlights
At a normal neuromuscular junction, a nerve impulse triggers the release of acetylcholine, which causes the muscles to contract.

Release of acetylcholine at the neuromuscular junction causes contraction of corrugator and procerus muscles, which over time can cause glabellar lines to form.

BOTOX^® Cosmetic is effective in reducing this activity. As it enters the nerve ending...

. . .BOTOX^® Cosmetic blocks the release of acetylcholine, reducing the activity of corrugator and procerus muscles.¹

1. BOTOX^® Cosmetic [package insert] Irvine, Calif: Allergan, Inc; 2002.

BOTOX^® Cosmetic is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in patients 18 to 65 years of age.

Important Safety Information

BOTOX^® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any ingredient in the formulation. There have been rare reports of adverse events involving the cardiovascular system. Serious and/or immediate hypersensitivity reactions have been reported rarely. These reactions include anaphylaxis, urticaria, soft-tissue edema, and dyspnea.

The most common adverse events following injection include blepharoptosis and nausea. Localized pain, infection, inflammation, tenderness, swelling, erythema and/or bleeding/bruising may be associated with the injection. Patients with neuromuscular disorders such as ALS, myasthenia gravis, or Lambert-Eaton syndrome may be at increased risk of serious adverse events.

Please see the additional safety information and full prescribing information.

Home | Prescribing Information | Privacy Policy | Contact Allergan | Site Map